PSNL: personalis.com Price/Earnings to Growth Multiple
Personalis, Inc. (PSNL) is optimizing its contractor workflows by expanding its partner network to ensure the seamless execution of oncology tests. The growth-adjusted P/E on GURU.Markets reflects this progress, with the value stabilizing at 0.00. The company's revenue is based on genomic sequencing for pharma behemoths, while premium pricing is sustained by the exceptional data accuracy of precision medicine.
Metric breakdowns and analytics for Personalis, Inc. (PSNL)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
PSNL - Company Net Income|Expected Net Profit Personalis, Inc.|PSNL - Price to Earnings Ratio|Price to Future Earnings Ratio Personalis Genomics|PSNL - PEG Multiple|EV/EBITDA Multiple Personalis Corp|PSNL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Personalis|PSNL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months personalis.com|PSNL - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Personalis, Inc.
General company analysis:PSNL - Personalis Inc
The high scientific potential of Personalis, Inc. (PSNL) in AI diagnostics and liquid biopsy necessitates a correlation between share price and earnings dynamics. The history of P/E to growth rate ratios allows for an assessment of whether the market capitalization justifies the speed of business expansion: a ratio below one signals that the asset is undervalued relative to its prospects, highlighting potentially fast-growing stocks provided that debt load remains controlled.
Competitors of Personalis, Inc.
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|ERAS (Erasca Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Corp DCTH|Price/Earnings to Growth Ratio Y-mAbs Therapeutics (YMAB)|AURA: Market Cap to Earnings and Growth Ratio|PEG Multiple CADL (Candel Therapeutics, Inc.)|Accuray Inc (ARAY) - Price to Earnings Adjusted for Growth Rate|SLS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ACTU (Actuate Therapeutics Inc)|Citius Oncology, Inc. (CTOR) - Price/Earnings to Growth Ratio|HURA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Protara Therapeutics, Inc.|Price to Earnings Adjusted for Growth Rate Fate Therapeutics Inc FATE|Price/Earnings to Growth Ratio Aadi Bioscience Inc (WHWK)|tscan.com - Growth-Adjusted P/E Ratio|PEG Multiple CSBR (Champions Oncology, Inc.)|PEG Multiple XBiotech Inc XBIT|CVM - Price/Earnings to Growth Ratio|OSTX: Price/Earnings to Growth Ratio|RADX: PEG Multiple|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Adlai Nortye Ltd|verupharma.com (VERU) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple TPST (Tempest Therapeutics, Inc.)|XLO (xiliotx.com) - Growth-Adjusted Payback Ratio|PEG Multiple RENB (Renovaro)|Growth-Adjusted Market Cap to Net Income Mural Oncology PLC (MURA)|KAPA - Price/Earnings to Growth Ratio|OKUR (OnKure Therapeutics Inc) - Growth-Adjusted P/E Ratio|GDTC: PEG Multiple|Price/Earnings to Growth Multiple Curis|Price/Earnings to Growth Multiple APLM|Tharimmune Corporation (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Advanced Biomed Inc (ADVB)|GNPX: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Calidi Biotherapeutics, Inc. CLDI|Growth-Adjusted Market Cap to Net Income Sunshine Biopharma Inc. (SBFM)|XBIO - Price/Earnings to Growth Ratio|SLRX (Salarius Pharma) - Growth-Adjusted P/E Ratio|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|AONC (American Oncology Network, Inc.) - Price/Earnings to Growth Ratio|BGNE (BeiGene) - PEG Multiple|Price/Earnings to Growth Multiple Checkpoint Therapeutics Inc. (CKPT)|PEG Multiple ELEV|PEG Multiple icadmed.com (ICAD)|Price/Earnings to Growth Ratio Ikena Oncology IKNA|NTBL: Growth-Adjusted P/E Ratio|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ascentage (AAPGV)
